(Q43202927)

English

Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial

scientific article published in January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 November 2017

Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial (English)

1 reference

Europe PubMed Central

16 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

11

1 reference

Europe PubMed Central

16 November 2017

author name string

Ligia Petrica

1

1 reference

Europe PubMed Central

16 November 2017

Maxim Petrica

2

1 reference

Europe PubMed Central

16 November 2017

Adrian Vlad

3

1 reference

Europe PubMed Central

16 November 2017

Catalin Dragos Jianu

4

1 reference

Europe PubMed Central

16 November 2017

Gheorghe Gluhovschi

5

1 reference

Europe PubMed Central

16 November 2017

Calina Ianculescu

6

1 reference

Europe PubMed Central

16 November 2017

Victor Dumitrascu

7

1 reference

Europe PubMed Central

16 November 2017

Sorin Giju

8

1 reference

Europe PubMed Central

16 November 2017

Cristina Gluhovschi

9

1 reference

Europe PubMed Central

16 November 2017

Flaviu Bob

10

1 reference

Europe PubMed Central

16 November 2017

Florica Gadalean

12

1 reference

Europe PubMed Central

16 November 2017

Silvia Velciov

13

1 reference

Europe PubMed Central

16 November 2017

Gheorghe Bozdog

14

1 reference

Europe PubMed Central

16 November 2017

Roxana Marian

15

1 reference

Europe PubMed Central

16 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2009

1 reference

Europe PubMed Central

16 November 2017

Vienna Clinical Weekly

1 reference

Europe PubMed Central

16 November 2017

121

1 reference

Europe PubMed Central

16 November 2017

23-24

1 reference

Europe PubMed Central

16 November 2017

765-775

1 reference

Europe PubMed Central

16 November 2017

https://scigraph.springernature.com/pub.10.1007/s00508-009-1279-3

0 references

Kidney disease in diabetology: lessons from 2007.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Public health aspects of diabetes mellitus--epidemiology, prevention strategies, policy implications: the first Austrian diabetes report.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Nonalbuminuric renal insufficiency in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Impaired tubular uptake explains albuminuria in early diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Beta2-microglobulin and cystatin C in type 2 diabetes: assessment of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Tubular function in diabetic children assessed by Tamm-Horsfall protein and glutathione S-transferase

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Serum cystatin C, enzymuria, tubular proteinuria and early renal insult in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Cerebrovascular reactivity is impaired in patients with non-insulin-dependent diabetes mellitus and microangiopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00508-009-1279-3

21 January 2018

Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Common carotid artery intima-media thickness and brain infarction : the Etude du Profil Génétique de l'Infarctus Cérébral (GENIC) case-control study. The GENIC Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of serum cystatin C to detect early decline of glomerular filtration rate in type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The comparison of cystatin C and creatinine as an accurate serum marker in the prediction of type 2 diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephropathy in diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Arterial pulsatility as an index of cerebral microangiopathy in diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cerebral microangiopathy in patients with non-insulin-dependent diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of thiazolidinediones on stroke recovery: a case-matched controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes and cardiovascular disease. The Framingham study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased intracranial arterial resistance in patients with type 2 diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resolved: normal glomeruli filter nephrotic levels of albumin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20047115

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00508-009-1279-3

1 reference

Europe PubMed Central

16 November 2017

1 reference

Europe PubMed Central

16 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43202927&oldid=1983675716"